Danial Khorsandi is currently a  Ph.D. student in School of Pharmacy, University of Barcelona, Spain. He has experience of working at the Harvard-MIT’s Division of Health Science and Technology, Harvard Medical School, Boston, USA.  

He is a member of PROCARE HEALTH IBERIA Company as a research fellow and medical affair.  PROCARE HEALTH was created in Spain with the vision of providing best innovative solutions to improve women’s health and well-being.

Currently, at the California NanoSystem Institute (CNSI) and the Center for Minimally Invasive Therapeutics (CMIT) at the UCLA, under supervision of Prof. Khademhosseini, he is working on developing the first Human uterine Cervix-on-a-chip. He is going to examine new opportunities for the application of organ-on-chip technologies in a range of areas in preclinical drug discovery, such as target identification and validation, target-based screening, and phenotypic screening. His investigations are mainly focused on Human Papiloma Virus (HPV) infection and the immune response of Human epithelial cells. The dynamic interactions between the uterine tissue cell types within the cervix can be precisely controlled and examined the effect of Papilocare® –a brand new product of Procare Health Iberia Company- as the first treatment to prevent and treat the HPV-Dependent cervical lesions, and also to check the condition of cells in cervical cancer, and cervical infection.

He joined the Khademhosseini laboratory in May 2018 as a researcher in the CNSI, University of California, Los Angeles.

Contact: khorsandi.d@procarehealth.es